Brainstorm Cell Therapeutics Inc. (BCLI)

NASDAQ: BCLI · IEX Real-Time Price · USD
3.10
-0.14 (-4.32%)
At close: Jan 21, 2022 4:00 PM
3.06
-0.04 (-1.29%)
After-hours:Jan 21, 2022 6:07 PM EST
Market Cap112.46M
Revenue (ttm)n/a
Net Income (ttm)-30.08M
Shares Out36.28M
EPS (ttm)-0.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume240,034
Open3.24
Previous Close3.24
Day's Range3.05 - 3.31
52-Week Range2.75 - 8.14
Beta-0.10
AnalystsBuy
Price Target11.00 (+254.8%)
Earnings DateFeb 2, 2022

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is ...

IndustryBiotechnology
Founded2000
CEOChaim Lebovits
Employees40
Stock ExchangeNASDAQ
Ticker SymbolBCLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for BCLI stock is "Buy" and the 12-month stock price forecast is 11.00.

Price Target
$11.00
(254.84% upside)
Analyst Consensus: Buy

News

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Ke...

2 weeks ago - PRNewsWire

FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program

NEW YORK, Dec. 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing ext...

3 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publ...

1 month ago - PRNewsWire

BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing

NEW YORK and SOMERSET, N.J., Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: ...

Other symbols:CTLT
1 month ago - PRNewsWire

BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on ...

1 month ago - PRNewsWire

BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium.  The NurOwn technology platf...

1 month ago - Benzinga

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at t...

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ne...

1 month ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for ...

2 months ago - PRNewsWire

BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments ...

2 months ago - PRNewsWire

Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Men...

2 months ago - PRNewsWire

BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will ...

2 months ago - PRNewsWire

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a ...

3 months ago - PRNewsWire

Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Commi...

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicent...

3 months ago - PRNewsWire

BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021

NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstr...

3 months ago - PRNewsWire

BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph...

3 months ago - PRNewsWire

BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstr...

3 months ago - PRNewsWire

BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for t...

5 months ago - PRNewsWire

BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel

NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received G...

5 months ago - PRNewsWire

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

NEW YORK, July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will h...

5 months ago - PRNewsWire

Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications ...

NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant an...

7 months ago - PRNewsWire

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUA...

NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a p...

7 months ago - PRNewsWire

BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for...

8 months ago - PRNewsWire

BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update

NEW YORK, April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will...

9 months ago - PRNewsWire

BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has reported topline Phase 2 data evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given two months apart, as a treatment for pro...

9 months ago - Benzinga

BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS

NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data f...

9 months ago - PRNewsWire